Acadia Pharmaceuticals (ACAD)

Company Description

ACADIA Pharmaceuticals (ACAD) focuses on the development and commercialization of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. Its lead drug candidate is NUPLAZID, which has delivered positive data in Phase III pivotal trials with a pristine safety profile for the treatment of Parkinson’s disease psychosis, an unmet medical need.   The potential blockbuster is also in Phase II development for Alzheimer’s disease psychosis and is currently planning a Phase II trial for the treatment of schizophrenia. ACAD also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc.

 

COMPANY ADDRESS
3611 Valley Centre Drive; Suite 300
San Diego, CA 92130
United States

COMPANY PHONE
(858) 558-2871

COMPANY WEBSITE


Get BioInvest's perspective on Acadia's CEO

Latest Company News

ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2016 Financial ... Yahoo Finance - 23 hours ago ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its ... ACADIA Pharmaceuticals Inc. (ACAD) Upgraded at Zacks Investment Research - The Cerbat Gem Stock Price of ACADIA Pharmaceuticals Inc. (ACAD) Increases 5.9% - Highland Mirror [...]
Tue, Feb 21, 2017 2:08:00 PM, Continue reading at the source
Is It Time to go for Valley National Bancorp (VLY), ACADIA Pharmaceuticals (ACAD)? StockNewsJournal - Feb 20, 2017 ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), maintained return on investment for the last twelve months at -59.19, higher than what Reuters data shows regarding industry's average. Analyst Views On Top Movers In Recent Trade: Valley National Bancorp (VLY ... - Post Analyst Analysts Stance on 2 Companies: Valley National Bancorp (NYSE:VLY), Callaway ... - The Voice Registrar [...]
Mon, Feb 20, 2017 2:39:00 PM, Continue reading at the source
Drilling Down Into ACADIA Pharmaceuticals Inc. (ACAD) StockNewsJournal - Feb 15, 2017 ACADIA Pharmaceuticals Inc. (ACAD) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $39.69, up from yesterday's close by 6.58%. [...]
Wed, Feb 15, 2017 5:48:00 PM, Continue reading at the source
Caution: Acadia Pharmaceuticals Is Overvalued Motley Fool - Feb 14, 2017 ... are on the sidelines considering buying in. If you're in the latter camp, take caution: Acadia Pharmaceuticals' dramatic rise is based on controversial phase 2 data, and a lot would have to go right for the company to maintain its current premium ... ACADIA Pharmaceuticals Inc. (ACAD) Moves Higher on Volume Spike for February 14 - Equities.com Acadia Pharmaceuticals: Still Room To Run? Or To Get Acquired? - Seeking Alpha [...]
Tue, Feb 14, 2017 12:56:00 PM, Continue reading at the source
ACADIA Pharmaceuticals Inc. (ACAD), Tempur Sealy International, Inc. (TPX ... The USA Commerce - Feb 13, 2017 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) dropped -2.27% to $37.09. During the trading on 02/10/2017, Company's stock ranged from $37.06 to $38.19. Trending Stocks Alert: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Tempur Sealy ... - The Newburgh Press 2 Stocks Analyst Opinion Asks for Deeper Look: ACADIA Pharmaceuticals Inc ... - The Voice Registrar [...]
Mon, Feb 13, 2017 3:56:00 PM, Continue reading at the source
Traders Secrets on ACADIA Pharmaceuticals Inc. (ACAD), Cadence Design Systems ... StockNewsJournal - Feb 10, 2017 ROI deals with the invested cash in the company and the return the investor realize on that money based on the net profit of the business. [...]
Fri, Feb 10, 2017 7:27:00 PM, Continue reading at the source
Takeover Talk Has Call Buyers Rushing ACADIA Pharmaceuticals Inc. (ACAD) Schaeffers Research (blog) - Feb 3, 2017 ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is higher today on M&A buzz, with sources reporting the biotech firm has received a takeover offer from AstraZeneca plc (ADR) (NYSE:AZN). ACADIA Pharmaceuticals Inc. (ACAD) Moves Higher on Volume Spike for February 03 - Equities.com ACADIA Pharmaceuticals (ACAD) Buyout: Why The AstraZeneca (AZN) Rumor Matters - BNL Finance (press release) (registration) (blog) [...]
Fri, Feb 03, 2017 7:53:00 PM, Continue reading at the source
Biotech Acquisitions on the Rise in 2017: Latest Reports on Antares Pharma and ... Yahoo Finance - Jan 31, 2017 Already in January we have seen a number of deals announced: Takeda Pharmaceutical's acquisition of Ariad Pharmaceuticals, Eli Lilly's acquisition of CoLucid Pharmaceuticals, Inc. and Valeant Pharmaceuticals decision to sell Dendreon Pharmaceuticals. [...]
Tue, Jan 31, 2017 2:42:00 PM, Continue reading at the source
How Risky Is Acadia Pharmaceuticals Stock? Motley Fool - Jan 30, 2017 Acadia Pharmaceuticals (NASDAQ:ACAD) is probably in better shape now than it's ever been. The biotech won ... In fact, Acadia's management team acknowledges that the company will continue to lose money for at least the next few years. Launching a new ... ACADIA Pharmaceuticals Inc. - Receive News & Ratings Daily - BBNS [...]
Mon, Jan 30, 2017 1:05:00 PM, Continue reading at the source
Acadia Pharmaceuticals (ACAD) Shares Cross Above 200 DMA Nasdaq - Jan 26, 2017 In trading on Thursday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed above their 200 day moving average of $31.32, changing hands as high as $32.10 per share. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Eps and Price target Analysis - TopChronicle ACADIA Pharmaceuticals' (ACAD) “Outperform” Rating Reiterated at Cowen and Company - The Cerbat Gem [...]
Thu, Jan 26, 2017 5:36:00 PM, Continue reading at the source